依折麦布联合辛伐他汀在肾功能减退患者中的获益
本研究基于IMPROVE-IT试验中18,015例肌酐清除率>30 ml/min的心血管疾病患者,事后分析eGFR与治疗终点关系,发现联合治疗相比单药治疗的主要终点相对风险降低随eGFR降低而不同(P=0.04),在eGFR≤75 ml/min尤其≤60 ml/min时差异明显,eGFR 60和45 ml/min时分别降低12%和13%风险。
要点
- eGFR≤75 ml/min时联合治疗获益优于单药,≤60 ml/min更明显。
- 基线eGFR 60 ml/min者联合治疗风险降低12%(HR 0.88)。
- 基线eGFR 45 ml/min者联合治疗风险降低13%(HR 0.87)。
核心结论
- 在eGFR≤75 ml/min的心血管疾病患者中,依折麦布联合辛伐他汀相比辛伐他汀单药可更显著降低主要心血管终点风险,且获益随eGFR降低而增大。
研究设计与样本
- 基于IMPROVE-IT试验的事后分析,纳入18,015例肌酐清除率>30 ml/min的心血管疾病患者,按eGFR评估治疗组间终点关系。
主要发现
- 主要终点(心血管死亡、主要冠脉事件或非致死性卒中)的相对风险降低在联合治疗与单药治疗间随eGFR不同而异(P=0.04)。
- 治疗效应差异见于eGFR≤75 ml/min per 1.73 m2,在≤60 ml/min per 1.73 m2时最明显。
- 基线eGFR 60 ml/min per 1.73 m2者联合治疗风险降低12%(HR 0.88;95%CI 0.82-0.95)。
- 基线eGFR 45 ml/min per 1.73 m2者联合治疗风险降低13%(HR 0.87;95%CI 0.78-0.98)。
- 急性冠脉综合征后10天内稳定的eGFR 30-60 ml/min per 1.73 m2患者中,联合治疗似乎比单药更有效。
临床怎么用
- 对于eGFR中度下降(30-60 ml/min per 1.73 m2)的心血管疾病患者,尤其是急性冠脉综合征后稳定者,可考虑依折麦布联合辛伐他汀以进一步降低心血管风险。
局限性
- 本研究为事后分析,结果需进一步研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Efficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems to diminish as eGFR declines. The strongest evidence supporting the cardiovascular benefit of statins in individuals with CKD was shown with ezetimibe plus simvastatin versus placebo. However, whether combination therapy or statin alone resulted in cardiovascular benefit is uncertain. Therefore, we estimated GFR in 18,015 individuals from the IMPROVE-IT (ezetimibe plus simvastatin versus simvastatin alone in individuals with cardiovascular disease and creatinine clearance >30 ml/min) and examined post hoc the relationship of eGFR with end points across treatment arms. For the primary end point of cardiovascular death, major coronary event, or nonfatal stroke, the relative risk reduction of combination therapy compared with monotherapy differed by eGFR (P=0.04). The difference in treatment effect was observed at eGFR≤75 ml/min per 1.73 m2 and most apparent at levels ≤60 ml/min per 1.73 m2 Compared with individuals receiving monotherapy, individuals receiving combination therapy with a baseline eGFR of 60 ml/min per 1.73 m2 experienced a 12% risk reduction (hazard ratio [HR], 0.88; 95% confidence interval [95% CI], 0.82 to 0.95); those with a baseline eGFR of 45 ml/min per 1.73 m2 had a 13% risk reduction (HR, 0.87; 95% CI, 0.78 to 0.98). In stabilized individuals within 10 days of acute coronary syndrome, combination therapy seemed to be more effective than monotherapy in individuals with moderately reduced eGFR (30-60 ml/min per 1.73 m2). Further studies examining potential benefits of combination lipid-lowering therapy in individuals with CKD are needed.
引用
- Stanifer JW, Charytan DM, White J, et al. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. J Am Soc Nephrol. 2017. PMID: 28507057. doi:10.1681/ASN.2016090957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。